Complement C5 Inhibitors & C5 Receptor Antagonists: a Competitor Analysis
2023-07-06
BARCELONA, Spain I July 6, 2023 I La Merie Publishing released its newest product reviewing the pipeline of complement C5 inhibitorscomplement C5 inhibitors and C5 receptor antagonists:
Competitor Analysis: Complement C5 InhibitorsComplement C5 Inhibitors & C5 Receptor Antagonists
This Competitive Intelligence report about Complement C5 InhibitorsComplement C5 Inhibitors & C5 Receptor Antagonists provides a competitor evaluation in the field of mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5 receptor as of July 2023.
With annual sales of more than US$ 5.7 bln in 2022, first and second generation C5 inhibitor antibodies Soliris and Ultomiris from AstraZeneca (acquired Alexion Pharmaceuticals) have set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Players in the field not only include small and medium biotech, but also Big Pharmas
This product consists of a competitor description in a tabular format provided as a pdf document and an one-month online access to La Merie Publishing’s online database for this product (report code: LMCA0012) (prerequisite: access to internet). Both deliverables (pdf and database credentials) are sent by e-mail within one day, usually within one hour.
The pdf report includes a compilation of currently active projects in research and development of inhibitors of complement C5 or antagonists of the C5a receptor. In addition, the pdf report lists company-specific R&D pipelines of C5 inhibitorsC5 inhibitors & C5R antagonists. Competitor projects are listed in a tabular format providing information on:
About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. The LMCA0012 report database provides access to the history of each project with links to the source of information (press release, homepage, abstracts, presentations, annual reports etc). Furthermore, the database allows export of data into a Word or Excel document.
The report “Competitor Analysis: Complement C5 InhibitorsComplement C5 Inhibitors & C5 Receptor Antagonists” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/competitor-analysis-complement-c5-inhibitors-c5-receptor-antagonists/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。